Oryzon Genomics SA
MAD:ORY
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Richter Gedeon Vegyeszeti Gyar Nyrt
OTC:RGEDF
|
HU |
|
F
|
Finework HuNan New Energy Technology Co Ltd
SZSE:301232
|
CN |
Oryzon Genomics SA
PP&E Gross
Oryzon Genomics SA
PP&E Gross Peer Comparison
Oryzon Genomics SA
Glance View
Oryzon Genomics SA is a clinical stage biopharmaceutical company, which engages in the discovery, research, and development of new chemical entities, as well as conducting clinical trials. The company is headquartered in Cornella De Llobregat, Barcelona and currently employs 44 full-time employees. The company went IPO on 2015-12-10. Its compounds in clinical development include iadademstat (ORY-lOOl), an LSD1 inhibitor that is in Phase II trials for the treatment of acute myeloid leukemia and small cell lung cancer; and vafidemstat (ORY-2001), an LSD1 inhibitor optimized for the Central Nervous System (CNS), in multiple Phase II clinical trials for the treatment of CNS and psychiatric illnesses. The firm also has ORY-3001, in preclinical development for the treatment of non-oncological diseases and has additional programs to develop inhibitors against other epigenetic targets.
See Also
What is Oryzon Genomics SA's PP&E Gross?
PP&E Gross
380.1k
EUR
Based on the financial report for Dec 31, 2025, Oryzon Genomics SA's PP&E Gross amounts to 380.1k EUR.
What is Oryzon Genomics SA's PP&E Gross growth rate?
PP&E Gross CAGR 10Y
-8%
Over the last year, the PP&E Gross growth was 7%. The average annual PP&E Gross growth rates for Oryzon Genomics SA have been -15% over the past three years , -10% over the past five years , and -8% over the past ten years .
